AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KOCT 303 min read$OABI

OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights

OmniAb, Inc. (OABI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights Raises Full Year 2026 Revenue and Cash Outlook on Continued Business Momentum Conference Call to Begin Today at 8:00 a.m. ET EMERYVILLE, Calif. (October 30, 2026) – OmniAb, Inc. (NASDAQ: OABI

Original reporting
SEC EDGAR 8-K
Published Oct 30, 2026, 11:42 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 11:48 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$OABI
Bullish
high confidence
Mentioned
$OABI · $LLY
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$OABIBullishHigh
01

Why it matters

The earnings beat, raised guidance, and a $370M potential partnership provide a strong bullish catalyst for both OmniAb and Eli Lilly.

02

Market read

The combined earnings and partnership news could lift biotech stocks and attract investor interest.

03

What to watch

Cash burn remains high; execution risk on new programs could temper enthusiasm.

Relevance 7/10Novelty 9/10Timing: pre-market today

Background

OmniAb, a Nasdaq‑listed antibody discovery company, filed its Q3 2026 8‑K reporting results and updated guidance.

Company-level read

Ticker impact

$OABIBullishHigh confidence
Context

OmniAb reported Q3 2026 results, raised full-year revenue guidance to $35‑39M and announced a new collaboration with Eli Lilly.

Expected impact

likely upward pressure as the market prices in higher guidance and potential $370M milestones

Evidence & confidence

Raised guidance and sizable deal provide a bullish catalyst for the stock.

$LLYBullishHigh confidence
Context

Eli Lilly entered a global collaboration and license agreement with OmniAb, receiving an up‑front payment and eligibility for up to $370M in milestones.

Expected impact

may see modest upside as investors value the new ion channel program partnership

Evidence & confidence

Deal adds potential revenue and strengthens Lilly's biotech portfolio, supporting a positive view.

Market effects

Sector

Biotech sector may benefit from increased collaboration activity and raised guidance.

Regional

US biotech market sees positive sentiment from the earnings beat and partnership.

Global

Potential influence on global biotech investment trends and pipeline development.

Counterpoint

What could challenge this read

If the partnership fails to deliver milestones, the upside could be limited.

Key entities

  • company
    OmniAb, Inc.

    Biotech firm reporting Q3 results and updated guidance.

  • company
    Eli Lilly and Company

    Pharmaceutical partner entering a collaboration with OmniAb.

Read at source← All news

Related articles

OCT 30
$LLYHighAI 9/10

Why is Eli Lilly stock gaining 3% today?

Eli Lilly (LLY) stock rose 3.2% in pre-market trading after Q3 earnings beat expectations, with revenue up 39% YoY to $24.4B and EPS at $7.48. The company raised 2026 revenue guidance to $91-92B. Analysts increased price targets, citing strong sales of diabetes and obesity drugs Mounjaro and Zepbound. Rival Novo Nordisk's weaker results highlighted Lilly's market leadership.

investing.com2 min
OCT 30
$LLYHighAI 8/10

Eli Lilly’s tirzepatide outperforms big pharma companies in Q3

Eli Lilly reported a 39% revenue increase in Q3 2026, driven by its obesity and diabetes medications Mounjaro and Zepbound, which generated $10.7bn and $5.4bn in sales respectively. The company raised its full-year revenue outlook to $91bn-$92bn. Analysts at Citi praised Lilly's performance, citing robust growth and a strong pipeline, including the upcoming Foundayo pill and breast cancer drug Inluriyo. Lilly has also made several acquisitions and expanded its manufacturing capabilities.

pharmaceutical-technology.com2 min
OCT 30
$LLYHighAI 8/10

What Sent Eli Lilly Stock Higher?

Eli Lilly (LLY) stock rose 6.6% on October 29, 2026, after reporting Q3 adjusted EPS of $7.48 (vs. $5.68 estimate) and revenue of $24.4B (vs. $22.6B estimate). Revenue grew 39% YoY, driven by Mounjaro and Zepbound. Management raised full-year revenue guidance to $91B-$92B. The stock closed at a one-year high of $1,373.70.

finance.yahoo.com2 min
OCT 30
$LLYHighAI 9/10

Eli Lilly and Co (LLY) (Q3 2026) Earnings Call Highlights: Revenue Jumps 39% as Mounjaro

Eli Lilly (NYSE:LLY) reported Q3 2026 revenue of $7B, up 39% YoY, driven by Mounjaro and Zepbound. The company raised full-year revenue guidance to $91-$92B and EPS guidance to $35-$36. Positive factors included the Medicare GLP-1 Bridge Program and pipeline advancements, while challenges included US price declines and potential future headwinds. Management highlighted long-term growth opportunities and increased manufacturing investments.

finance.yahoo.com9 min
OCT 30
$LLYMed

BMO raises Eli Lilly stock price target on metabolic strength

BMO Capital raised its price target for Eli Lilly (NYSE:LLY) to $1,650, citing strong metabolic disease franchise performance and recent guidance increases. The stock, trading at $1,373.70, has surged 64% over the past year. Eli Lilly's revenue grew 46% to $86.5 billion, with an 84% gross profit margin. The company's Q3 2026 earnings of $7.48 per share beat expectations, with revenue of $24.4 billion. Several analysts raised their price targets following the strong results.

investing.com2 min